Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
CDC changes kids' vaccine schedule, removing universal recommendation for some shots - 2Deadly Switzerland ski resort fire was likely started by sparklers attached to champagne bottles, officials say
- 3'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- 4Jersey's wellbeing score is below UK and France
- 5State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing
- Exploring School Life: Self-awareness and Illustrations
- The most effective method to Pick the Right Teeth Substitution Choice for You
- Dependable Savvy Locks to Update Your Home Security
- Audits of 6 European Busssiness Class Flights
- Germany raises prospect of military forces to secure Ukraine peace
- NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby
- Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers
- Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
